A new antitumor antibiotic, FR-900482. IV. Hematological toxicity in mice.
The new antibiotic FR-900482 (4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo-[7.4.1.02,7. O10,12]tetradeca-2,4,6-triene-8-ylmethyl carbamate) possesses an antitumor activity equal to or greater than that of mitomycin C (MMC). The hematotoxicity of equivalent effective doses of the two compounds was compared in mice. A single iv injection of either compound similarly decreased the number of white blood cells (WBC) in the peripheral blood, whereas FR-900482 had no effect on the number of platelets (PTL). Both drugs slightly reduced the number of red blood cells (RBC). The effect of FR-900482 on the bone marrow cells (BMC) measured by cfu in spleen and cfu in culture was weaker than that of MMC. The results suggest that FR-900482 is a promising antitumor agent both in efficacy and safety.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D001772:Blood Cell Count / Q000187:drug effects; D001854:Bone Marrow Cells; D001643:Bridged Bicyclo Compounds / Q000633:toxicity; D003114:Colony-Forming Units Assay; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D010078:Oxazines; D010976:Platelet Count / Q000187:drug effects; D013154:Spleen / Q000166:cytology
D000903:Antibiotics, Antineoplastic; D001643:Bridged Bicyclo Compounds; D008937:Mitomycins; D010078:Oxazines; C053335:FR 900482; D016685:Mitomycin